Prostate Cancer - Results from #440

Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies. August 22, 2024

Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort. August 21, 2024

Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial). August 21, 2024

Prostate-Specific Antigen Screening and Prostate Cancer Mortality: An Emulation of Target Trials in US Medicare. August 21, 2024

Moderately hypofractionated dose escalation radiotherapy for localized prostate cancer, ESHYPRO: Results of a retrospective single-centre series evaluating safety and efficacy. August 21, 2024

Clinical decision making in prostate cancer care-evaluation of EAU-guidelines use and novel decision support software. August 21, 2024

Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer. August 21, 2024

Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together? August 20, 2024

Long noncoding RNA EPCART regulates translation through PI3K/AKT/mTOR pathway and PDCD4 in prostate cancer. August 20, 2024

Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No. August 20, 2024

Update on PI-RADS Version 2.1 Diagnostic Performance Benchmarks for Prostate MRI: Systematic Review and Meta-Analysis. August 20, 2024

Evaluation of prostate cancer detection using micro-ultrasound versus MRI through co-registration to whole-mount pathology. August 20, 2024

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate. August 19, 2024

Evaluating the added value of concurrent contrast-enhanced diagnostic CT for PSMA-PET/CT Interpretation. August 19, 2024

How a population-based cohort of men estimate lifetime risk of prostate cancer in a survey before entering a prostate cancer screening trial in Sweden? August 19, 2024

Understanding and Addressing Prostate Cancer Disparities in Diagnosis, Treatment, and Outcomes Among Black Men. August 19, 2024

Using gene and gene-set association tests to identify lethal prostate cancer genes. August 19, 2024

Validation of candidate protein biomarkers previously identified by genetic instruments for prostate cancer risk: A prospective cohort analysis of directly measured protein levels in the ARIC study. August 19, 2024

Contemporary treatment standards and trends of systemic therapy in metastatic hormone-sensitive prostate cancer-implementing study data in clinical practice. August 16, 2024

Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. August 16, 2024

Page 23 of 1438